Vigilancia de laboratorio de Streptococcus pneumoniae procedente de enfermedad invasora, Chile 2007-2012

Valenzuela, María Teresa; Seoane, Mabel; Canals, Andrea; Pidal, Paola; Hormázabal, Juan Carlos; Araya, Pamela; Terrazas, Solana; Díaz, Janepsy

doi:10.4067/s0716-10182014000600002

Cited by 10 publications

(21 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Four studies addressed invasive pneumococcal disease (IPD) hospitalizations [15, 32, 44, 45], none of which analyzed IPD mortality. Reported baseline IPD rates ranged from 3.9 (predicted rates based on time-series modelling for children aged 2–4 years) to 68.7 (children <2 years old in Uruguay) per 100,000 children (Table 4).…”

Section: Resultsmentioning

confidence: 99%

“…*Study by Valenzuela et al [45] did not report confidence interval and was not plotted. Countries: BRA (Brazil); URU (Uruguay).…”

Section: Resultsmentioning

confidence: 99%

“…Both interrupted time series studies conducted in Chile [45] and Brazil [32] showed a decreasing trend after PCV introduction in children aged <2 years contrasting with non-decreasing trend in rates in age groups not targeted by PCV. That resulted in consistently high VE in both studies (Table 4).…”

Section: Resultsmentioning

confidence: 99%

“…A study in Chile [45] reported important decrease in serotype specific pneumococcal IPD after PCV-10 introduction in children under 2 years of age, particularly for serotypes 4 (5 cases in the pre-PCV to 0 cases in the post-PCV period), 19F (15 to 1), 23F (11 to 1), 14 (74 to 14), 6B (20 to 6), 18C (12 to 5), and 1 (11 to 2). Serotype 19A cases decreased from 13 to 8.…”

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Impact and Effectiveness of 10 and 13-Valent Pneumococcal Conjugate Vaccines on Hospitalization and Mortality in Children Aged Less than 5 Years in Latin American Countries: A Systematic Review

et al. 2016

View full text Add to dashboard Cite

BackgroundSeveral Latin American and Caribbean (LAC) countries have introduced pneumococcal conjugate vaccine (PCV-10 or PCV-13) in their routine national immunization programs.ObjectivesWe aimed to summarize the evidence of PCV impact and effectiveness in children under 5 years old in the LAC Region.MethodsWe conducted a systematic review of the literature on impact or effectiveness of PCVs on deaths or hospitalizations due to invasive pneumococcal disease (IPD), pneumonia, meningitis and sepsis. We searched Medline, WoS, Lilacs, Scopus, Central and gray literature published in any language from 2009 to January 2016. We included studies addressing the outcomes of interest in children in the target age group, and with the following designs: randomized trials, cohort or case-control, interrupted time series with at least three data points before and after the intervention, and before-after studies. Screening of citations, data extraction, and risk of bias assessment were conducted in duplicate by independent reviewers, according to the study protocol registered on PROSPERO. Descriptive analysis of the effectiveness measurements and sensitivity analysis were conducted. Effectiveness is reported as 1-OR or 1-RR for case control or cohort/clinical trials, and as percent change of disease incidence rates for before-after studies.ResultsWe identified 1,085 citations, 892 from databases and 193 from other sources. Of these, 22 were further analyzed. Studies were from Brazil, Chile, Uruguay, Argentina, Peru and Nicaragua. Effectiveness ranged from 8.8–37.8% for hospitalizations due to X-ray confirmed pneumonia, 7.4–20.6% for clinical pneumonia, and 13.3–87.7% for meningitis hospitalizations, and 56–83.3% for IPD hospitalization, varying by age, outcome definition, type of vaccine and study design.ConclusionsAvailable evidence to date indicates significant impact of both PCV-10 and PCV-13 in the outcomes studied, with no evidence of the superiority of one vaccine over the other on pneumonia, IPD or meningitis hospitalization reduction in children under 5 years old.

show abstract

Section: Resultsmentioning

confidence: 99%

“…*Study by Valenzuela et al [45] did not report confidence interval and was not plotted. Countries: BRA (Brazil); URU (Uruguay).…”

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Impact and Effectiveness of 10 and 13-Valent Pneumococcal Conjugate Vaccines on Hospitalization and Mortality in Children Aged Less than 5 Years in Latin American Countries: A Systematic Review

et al. 2016

View full text Add to dashboard Cite

show abstract

“…7 . No hay estudios chilenos publicados de casos clínicos de pacientes adultos con MBA por S. pneumoniae resistente a Cef-3g.…”

Section: Mala Respuesta a Ceftriaxona En Adultos Con Meningitis Por Sunclassified

Mala respuesta a ceftriaxona en adultos con meningitis por Streptococcus pneumoniae

Hadad¹,

Gualda²

2015

Rev. chil. infectol.

View full text Add to dashboard Cite

Streptococcus pneumoniae serotype 19A in Latin America and the Caribbean 2010–2015: A systematic review and a time series analysis

Agudelo

DeAntonio²,

Castañeda

2018

Vaccine

View full text Add to dashboard Cite

show abstract

Vigilancia de laboratorio de Streptococcus pneumoniae procedente de enfermedad invasora, Chile 2007-2012

Cited by 10 publications

References 18 publications

Impact and Effectiveness of 10 and 13-Valent Pneumococcal Conjugate Vaccines on Hospitalization and Mortality in Children Aged Less than 5 Years in Latin American Countries: A Systematic Review

Impact and Effectiveness of 10 and 13-Valent Pneumococcal Conjugate Vaccines on Hospitalization and Mortality in Children Aged Less than 5 Years in Latin American Countries: A Systematic Review

Mala respuesta a ceftriaxona en adultos con meningitis por Streptococcus pneumoniae

Streptococcus pneumoniae serotype 19A in Latin America and the Caribbean 2010–2015: A systematic review and a time series analysis

Contact Info

Product

Resources

About